nach oben

Erschienen in:

22.02.2020 | Original Article

Prevalence of anti-DFS70 autoantibodies in a Latin American cohort of patients with systemic lupus erythematosus and without autoimmune diseases

verfasst von: Cristian C. Aragón, Iván Posso-Osorio, Germán Puerta, Juan-David González, Juan-Camilo Naranjo, Alex Echeverri, Eliana Ortíz, Ivana Nieto-Aristizábal, María Claudia Barrera, Lady J. Ríos-Serna, Gabriel J. Tobón

Erschienen in: Clinical Rheumatology | Ausgabe 7/2020

Einloggen, um Zugang zu erhalten

Abstract

Introduction/objectives

Anti-dense fine speckled 70 (DFS70) autoantibodies were reported to be more prevalent in healthy individuals than those with autoimmune diseases such as systemic lupus erythematosus (SLE). We determined anti-DFS70 autoantibody prevalence in a Latin American cohort of patients with SLE and healthy individuals.

Methods

This study included 127 individuals with anti-nuclear antibodies (ANAs; > 1:160) suggesting the presence of anti-DFS70, including 64 patients with SLE and 63 healthy controls. The anti-DFS70 autoantibodies were determined by immunoadsorption using NOVA Lite^® HEp-2 Select kit with DAPI. Negative fluorescence after adsorption with the DFS70 antigen indicated anti-DFS70 autoantibody positivity.

Results

The presence of anti-DFS70 autoantibodies was confirmed by indirect immunofluorescence in 21 (33.3%) healthy controls and 8 (12.5%) patients with SLE (p = 0.005). Among the anti-DFS70-positive patients with SLE, the most frequent compromise was renal involvement in six cases (75%), 4 patients (37.5%) were positive for anti-Sm, which was the most frequently associated antibody, and one patient (12.5%) was positive for anti-DNA.

Conclusions

Anti-DFS70 autoantibodies might be considered a biomarker to differentiate patients with SLE from ANA-positive individuals without autoimmune diseases.

Key Points:

• In a Latin American cohort, the anti-DFS70 was higher in individuals without autoimmune diseases compared with that in patients with SLE.

• The anti-DFS70 might have utility as a biomarker of exclusion in patients with non-specific clinical signs of AARDs.

Mahler M, Meroni P-L, Bossuyt X, Fritzler MJ (2014) Current concepts and future directions for the assessment of autoantibodies to cellular antigens referred to as anti-nuclear antibodies. J Immunol Res 2014:1–18. https://doi.org/10.1155/2014/315179 CrossRef

Petri M, Orbai AM, Alarcõn GS et al (2012) Derivation and validation of the systemic lupus international collaborating clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum 64:2677–2686. https://doi.org/10.1002/art.34473 CrossRefPubMedPubMedCentral

Meroni PL, Schur PH (2010) ANA screening: an old test with new recommendations. Ann Rheum Dis 69:1420–1422. https://doi.org/10.1136/ard.2009.127100 CrossRefPubMed

Tan EM, Feltkamp TE, Smolen JS, Butcher B, Dawkins R, Fritzler MJ, Gordon T, Hardin JA, Kalden JR, Lahita RG, Maini RN, McDougal J, Rothfield NF, Smeenk RJ, Takasaki Y, Wiik A, Wilson MR, Koziol JA (1997) Range of antinuclear antibodies in “healthy” individuals. Arthritis Rheum 40:1601–1611. https://doi.org/10.1002/1529-0131(199709)40:9<1601::AID-ART9>3.0.CO;2-T CrossRefPubMed

Satoh M, Chan EKL, Ho LA, Rose KM, Parks CG, Cohn RD, Jusko TA, Walker NJ, Germolec DR, Whitt IZ, Crockett PW, Pauley BA, Chan JY, Ross SJ, Birnbaum LS, Zeldin DC, Miller FW (2012) Prevalence and sociodemographic correlates of antinuclear antibodies in the United States. Arthritis Rheum 64:2319–2327. https://doi.org/10.1002/art.34380 CrossRefPubMedPubMedCentral

Damoiseaux J, von Mühlen CA, Garcia-De La Torre I et al (2016) International consensus on ANA patterns (ICAP): the bumpy road towards a consensus on reporting ANA results. Autoimmun Highlights 7:1. https://doi.org/10.1007/s13317-016-0075-0 CrossRef

Watanabe A, Kodera M, Sugiura K, Usuda T, Tan EM, Takasaki Y, Tomita Y, Muro Y (2004) Anti-DFS70 antibodies in 597 healthy hospital workers. Arthritis Rheum 50:892–900. https://doi.org/10.1002/art.20096 CrossRefPubMed

Ochs RL, Muro Y, Si Y, Ge H, Chan EK, Tan EM (2000) Autoantibodies to DFS 70 kd/transcription coactivator p75 in atopic dermatitis and other conditions. J Allergy Clin Immunol 105:1211–1220CrossRef

Ganapathy V, Casiano CA (2004) Autoimmunity to the nuclear autoantigen DFS70 (LEDGF): what exactly are the autoantibodies trying to tell us? Arthritis Rheum 50:684–688. https://doi.org/10.1002/art.20095 CrossRefPubMed

10.

Basu A, Sanchez TW, Casiano CA (2015) DFS70/LEDGFp75: an enigmatic autoantigen at the interface between autoimmunity, AIDS, and cancer. Front Immunol 6:116. https://doi.org/10.3389/fimmu.2015.00116 CrossRefPubMedPubMedCentral

11.

Mahler M, Parker T, Peebles CL, Andrade LE, Swart A, Carbone Y, Ferguson DJ, Villalta D, Bizzaro N, Hanly JG, Fritzler MJ (2012) Anti-DFS70/LEDGF antibodies are more prevalent in healthy individuals compared to patients with systemic autoimmune rheumatic diseases. J Rheumatol 39:2104–2110. https://doi.org/10.3899/jrheum.120598 CrossRefPubMed

12.

Mahler M, Hanly JG, Fritzler MJ (2012) Importance of the dense fine speckled pattern on HEp-2 cells and anti-DFS70 antibodies for the diagnosis of systemic autoimmune diseases. Autoimmun Rev 11:642–645. https://doi.org/10.1016/j.autrev.2011.11.005 CrossRefPubMed

13.

Mariz HA, Sato EI, Barbosa SH, Rodrigues SH, Dellavance A, Andrade LE (2011) Pattern on the antinuclear antibody-HEp-2 test is a critical parameter for discriminating antinuclear antibody-positive healthy individuals and patients with autoimmune rheumatic diseases. Arthritis Rheum 63:191–200. https://doi.org/10.1002/art.30084 CrossRefPubMed

14.

López Sañudo S, Fernández Alonso I, López Hoyos M (2015) Importancia del patrón moteado fino denso y de los anticuerpos anti-DFS70 en el diagnóstico de enfermedades autoinmunitarias del tejido conectivo. Med Clin (Barc) 145:218–223. https://doi.org/10.1016/j.medcli.2015.03.009 CrossRef

15.

Hochberg MC (1997) Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 40:1725. https://doi.org/10.1002/1529-0131(199709)40:9<1725::AID-ART29>3.0.CO;2-Y CrossRefPubMed

16.

Bizzaro N, Tonutti E, Visentini D et al (2007) Antibodies to the lens and cornea in anti-DFS70-positive subjects. Ann N Y Acad Sci 183:174–183. https://doi.org/10.1196/annals.1381.019 CrossRef

17.

Ochs RL, Mahler M, Basu A, Rios-Colon L, Sanchez TW, Andrade LE, Fritzler MJ, Casiano CA (2016) The significance of autoantibodies to DFS70/LEDGFp75 in health and disease: integrating basic science with clinical understanding. Clin Exp Med 16:273–293. https://doi.org/10.1007/s10238-015-0367-0 CrossRefPubMed

18.

Maertens G, Cherepanov P, Pluymers W, Busschots K, de Clercq E, Debyser Z, Engelborghs Y (2003) LEDGF/p75 is essential for nuclear and chromosomal targeting of HIV-1 integrase in human cells. J Biol Chem 278:33528–33539. https://doi.org/10.1074/jbc.M303594200 CrossRefPubMed

19.

Basu A, Rojas H, Banerjee H, Cabrera IB, Perez KY, de León M, Casiano CA (2012) Expression of the stress response oncoprotein LEDGF/p75 in human cancer: a study of 21 tumor types. PLoS One 7:e30132. https://doi.org/10.1371/journal.pone.0030132 CrossRefPubMedPubMedCentral

20.

Ge H, Si Y, Roeder RG (1998) Isolation of cDNAs encoding novel transcription coactivators p52 and p75 reveals an alternate regulatory mechanism of transcriptional activation. EMBO J 17:6723–6729. https://doi.org/10.1093/emboj/17.22.6723 CrossRefPubMedPubMedCentral

21.

Dellavance A, Viana VST, Leon EP, Bonfa ES, Andrade LE, Leser PG (2005) The clinical spectrum of antinuclear antibodies associated with the nuclear dense fine speckled immunofluorescence pattern. J Rheumatol 32:2144–2149PubMed

22.

Muro Y, Sugiura K, Nakashima RAN, et al (2013) Low prevalence of anti-DFS70/LEDGF antibodies in patients with dermatomyositis and other systemic autoimmune rheumatic diseases The Journal of Rheumatology is a monthly international serial edited by Duncan A. Gordon featuri 40:4–6

23.

Lee H, Kim Y, Han K, Oh E-J (2016) Application of anti-DFS70 antibody and specific autoantibody test algorithms to patients with the dense fine speckled pattern on HEp-2 cells. Scand J Rheumatol 45:122–128. https://doi.org/10.3109/03009742.2015.1060260 CrossRefPubMed

24.

Conrad K, Röber N, Andrade LEC, Mahler M (2017) The clinical relevance of anti-DFS70 autoantibodies. Clin Rev Allergy Immunol 52:202–216. https://doi.org/10.1007/s12016-016-8564-5 CrossRefPubMed

25.

Mahler M, Andrade LE, Casiano CA, Malyavantham K, Fritzler MJ (2019) Anti-DFS70 antibodies: an update on our current understanding and their clinical usefulness. Expert Rev Clin Immunol 15:241–250. https://doi.org/10.1080/1744666X.2019.1562903 CrossRefPubMed

26.

Gundín S, Irure-Ventura J, Asensio E et al (2016) Measurement of anti-DFS70 antibodies in patients with ANA-associated autoimmune rheumatic diseases suspicion is cost-effective. Autoimmun Highlights 7. https://doi.org/10.1007/s13317-016-0082-1

27.

Watanabe K, Muro Y, Sugiura K, Tomita Y (2011) IgE and IgG ₄ autoantibodies against DFS70/LEDGF in atopic dermatitis. Autoimmunity 44:511–519. https://doi.org/10.3109/08916934.2010.549157 CrossRefPubMed

28.

Bentow C, Fritzler MJ, Mummert E, Mahler M (2016) Recognition of the dense fine speckled (DFS) pattern remains challenging: results from an international internet-based survey. Autoimmun Highlights 7:8. https://doi.org/10.1007/s13317-016-0081-2 CrossRef

29.

Muro Y, Sugiura K, Morita Y, Tomita Y (2008) High concomitance of disease marker autoantibodies in anti-DFS70/LEDGF autoantibody–positive patients with autoimmune rheumatic disease. Lupus 17:171–176. https://doi.org/10.1177/0961203307086311 CrossRefPubMed

30.

Bentow C, Rosenblum R, Correia P, Karayev E, Karayev D, Williams D, Kulczycka J, Fritzler MJ, Mahler M (2016) Development and multi-center evaluation of a novel immunoadsorption method for anti-DFS70 antibodies. Lupus 25:897–904. https://doi.org/10.1177/0961203316641773 CrossRefPubMed

31.

Bizzaro N, Tonutti E, Tampoia M et al (2015) Specific chemiluminescence and immunoadsorption tests for anti-DFS70 antibodies avoid false positive results by indirect immunofluorescence. Clin Chim Acta 451:271–277. https://doi.org/10.1016/j.cca.2015.10.008 CrossRefPubMed

32.

Choi MY, Clarke A, St Pierre Y et al (2017) The prevalence and determinants of anti-DFS70 autoantibodies in an international inception cohort of systemic lupus erythematosus patients. Lupus:1–9. https://doi.org/10.1177/0961203317692437

33.

Tsokos GC (2011) Systemic lupus erythematosus. N Engl J Med 365:2110–2121. https://doi.org/10.1017/CBO9781107415324.004 CrossRefPubMed

Titel: Prevalence of anti-DFS70 autoantibodies in a Latin American cohort of patients with systemic lupus erythematosus and without autoimmune diseases
verfasst von: Cristian C. Aragón
Iván Posso-Osorio
Germán Puerta
Juan-David González
Juan-Camilo Naranjo
Alex Echeverri
Eliana Ortíz
Ivana Nieto-Aristizábal
María Claudia Barrera
Lady J. Ríos-Serna
Gabriel J. Tobón
Publikationsdatum: 22.02.2020
Verlag: Springer London
Erschienen in: Clinical Rheumatology / Ausgabe 7/2020
Print ISSN: 0770-3198
Elektronische ISSN: 1434-9949
DOI: https://doi.org/10.1007/s10067-020-04990-z

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

19.04.2024 | Vorhofflimmern | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Prevalence of anti-DFS70 autoantibodies in a Latin American cohort of patients with systemic lupus erythematosus and without autoimmune diseases

Abstract

Introduction/objectives

Methods

Results

Conclusions

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Parodontalbehandlung verbessert Prognose bei Katheterablation

Prostatakarzinom: EU initiiert neues Screeningkonzept

Blasenkarzinom – Biomarker statt Zytologie?

Antihypertensiva schützen auch alte Menschen noch vor Demenz

Update Innere Medizin

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Introduction/objectives

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 7/2020

Catastrophic antiphospholipid syndrome: is life-long anticoagulation therapy required?

Orbital compartment syndrome as the first manifestation of SLE

The systemic sclerosis patient in the COVID-19 era: the challenging crossroad between immunosuppression, differential diagnosis and long-term psychological distress

Diagnosing relapsing polychondritis remains a common challenge: experience from a Chinese retrospective cohort

Spatio-temporal evolution of onychomadesis in a child with missed Kawasaki disease

Corticosteroid treatment in severe COVID-19 pneumonia: two cases and literature review

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Parodontalbehandlung verbessert Prognose bei Katheterablation

Prostatakarzinom: EU initiiert neues Screeningkonzept

Blasenkarzinom – Biomarker statt Zytologie?

Antihypertensiva schützen auch alte Menschen noch vor Demenz

Update Innere Medizin